TY - JOUR
T1 - Erratum to “siRNA therapeutics for breast cancer
T2 - recent efforts in targeting metastasis, drug resistance, and immune evasion” [Translational Research 214C (2019) 105-120](S1931524419301689)(10.1016/j.trsl.2019.08.005)
AU - Ngamcherdtrakul, Worapol
AU - Yantasee, Wassana
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/3
Y1 - 2020/3
N2 - The publisher regrets that the author information was incorrect in the footnote. This has been corrected for the online version. The correct information is “Worapol Ngamcherdtrakul, PhD, is a scientist at PDX Pharmaceuticals. Dr. Ngamcherdtrakul's research is focused on developing nanoparticles for cancer-targeted co-delivery of drug and siRNA and developing topical formulations of a nanotechnology for skin diseases. He also leads the cancer immunotherapy program at PDX Pharmaceuticals”. The publisher would like to apologise for any inconvenience caused.
AB - The publisher regrets that the author information was incorrect in the footnote. This has been corrected for the online version. The correct information is “Worapol Ngamcherdtrakul, PhD, is a scientist at PDX Pharmaceuticals. Dr. Ngamcherdtrakul's research is focused on developing nanoparticles for cancer-targeted co-delivery of drug and siRNA and developing topical formulations of a nanotechnology for skin diseases. He also leads the cancer immunotherapy program at PDX Pharmaceuticals”. The publisher would like to apologise for any inconvenience caused.
UR - http://www.scopus.com/inward/record.url?scp=85079391892&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079391892&partnerID=8YFLogxK
U2 - 10.1016/j.trsl.2020.01.004
DO - 10.1016/j.trsl.2020.01.004
M3 - Comment/debate
C2 - 32081297
AN - SCOPUS:85079391892
SN - 1931-5244
VL - 217
SP - 77
JO - Translational Research
JF - Translational Research
ER -